{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT01490177",
      "orgStudyIdInfo": {
        "id": "22871"
      },
      "organization": {
        "fullName": "Stanford University",
        "class": "OTHER"
      },
      "briefTitle": "Single Center Food Allergy Oral Immunotherapy Study",
      "officialTitle": "Single Center, Phase I Food Allergy Oral Immunotherapy Study"
    },
    "statusModule": {
      "statusVerifiedDate": "2015-11",
      "overallStatus": "COMPLETED",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2011-11"
      },
      "primaryCompletionDateStruct": {
        "date": "2014-04",
        "type": "ACTUAL"
      },
      "completionDateStruct": {
        "date": "2014-04",
        "type": "ACTUAL"
      },
      "studyFirstSubmitDate": "2011-11-29",
      "studyFirstSubmitQcDate": "2011-12-08",
      "studyFirstPostDateStruct": {
        "date": "2011-12-12",
        "type": "ESTIMATED"
      },
      "lastUpdateSubmitDate": "2015-11-24",
      "lastUpdatePostDateStruct": {
        "date": "2015-11-26",
        "type": "ESTIMATED"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "PRINCIPAL_INVESTIGATOR",
        "investigatorFullName": "Kari Christine Nadeau",
        "investigatorTitle": "Associate Professor",
        "investigatorAffiliation": "Stanford University"
      },
      "leadSponsor": {
        "name": "Stanford University",
        "class": "OTHER"
      }
    },
    "oversightModule": {
      "oversightHasDmc": true
    },
    "descriptionModule": {
      "briefSummary": "The Primary Objective of the study is to develop a customized regimen for oral immunotherapy that reflects what the subject is allergic in a clinically significant way (i.e., the offending food allergen is defined as a food allergen with a positive skin test or positive specific IgE and a positive DBPCFC). Therefore, the investigators prefer that both single and multiple food allergy subjects are included in the study."
    },
    "conditionsModule": {
      "conditions": [
        "Immune System Diseases"
      ],
      "keywords": [
        "Multiple food allergies"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "designInfo": {
        "allocation": "NA",
        "interventionModel": "SINGLE_GROUP",
        "primaryPurpose": "TREATMENT",
        "maskingInfo": {
          "masking": "NONE"
        }
      },
      "enrollmentInfo": {
        "count": 50,
        "type": "ACTUAL"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "One",
          "type": "EXPERIMENTAL",
          "interventionNames": [
            "Drug: Food proteins"
          ]
        }
      ],
      "interventions": [
        {
          "type": "DRUG",
          "name": "Food proteins",
          "description": "Oral ingestion of Food proteins",
          "armGroupLabels": [
            "One"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Number of adverse events in the treatment population",
          "timeFrame": "2 years"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "Number of subjects who reach 2g or more of food flour",
          "timeFrame": "2 years"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n* Moderate to severe peanut and/or egg and/or milk and/or tree nut and/or seed allergic subjects between the ages of 4 to 55 years old.\n* Sensitivity to food allergen will be documented by a positive skin prick test result (see Appendix for details) or allergen specific ImmunoCAP IgE level with 7 kU/L as a lower limit of eligibility.\n\nExclusion Criteria:\n\n* No absolute contraindications are known. However, the risk of serious systemic anaphylactic reactions to food allergens suggests a number of preexisting conditions that should be considered relative contraindications. Among those conditions are acute infections, autoimmune disease, severe cardiac disease, and treatment with beta-adrenergic antagonistic drugs (beta-blockers).\n* Subjects having a history of severe anaphylaxis to food allergens that will be desensitized in this study requiring intubation or admission to an ICU, frequent allergic or non-allergic urticaria, or history consistent with poorly controlled persistent asthma.",
      "healthyVolunteers": false,
      "sex": "ALL",
      "minimumAge": "4 Years",
      "maximumAge": "55 Years",
      "stdAges": [
        "CHILD",
        "ADULT"
      ]
    },
    "contactsLocationsModule": {
      "locations": [
        {
          "facility": "Stanford University School of Medicine",
          "city": "Stanford",
          "state": "California",
          "zip": "94305",
          "country": "United States",
          "geoPoint": {
            "lat": 37.42411,
            "lon": -122.16608
          }
        }
      ]
    },
    "referencesModule": {
      "references": [
        {
          "pmid": "24428859",
          "type": "DERIVED",
          "citation": "Begin P, Winterroth LC, Dominguez T, Wilson SP, Bacal L, Mehrotra A, Kausch B, Trela A, Hoyte E, O'Riordan G, Seki S, Blakemore A, Woch M, Hamilton RG, Nadeau KC. Safety and feasibility of oral immunotherapy to multiple allergens for food allergy. Allergy Asthma Clin Immunol. 2014 Jan 15;10(1):1. doi: 10.1186/1710-1492-10-1."
        }
      ]
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2026-02-04"
    },
    "conditionBrowseModule": {
      "meshes": [
        {
          "id": "D007154",
          "term": "Immune System Diseases"
        }
      ]
    }
  },
  "hasResults": false
}